Tumor stroma–targeted antibody-drug conjugate triggers localized anticancer drug release
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Although nonmalignant stromal cells facilitate tumor growth and can occupy up to 90% of a solid tumor mass, better strategies to exploit these cells for improved cancer therapy are needed. Here, we describe a potent MMAE-linked antibody-drug conjugate (ADC) targeting tumor endothelial marker 8 (TEM8, also known as ANTXR1), a highly conserved transmembrane receptor broadly overexpressed on cancer-associated fibroblasts, endothelium, and pericytes. Anti-TEM8 ADC elicited potent anticancer activity through an unexpected killing mechanism we term DAaRTS (drug activation and release through stroma), whereby the tumor microenvironment localizes active drug at the tumor site. Following capture of ADC prodrug from the circulation, tumor-associated stromal cells release active MMAE free drug, killing nearby proliferating tumor cells in a target-independent manner. In preclinical studies, ADC treatment was well tolerated and induced regression and often eradication of multiple solid tumor types, blocked metastatic growth, and prolonged overall survival. By exploiting TEM8+ tumor stroma for targeted drug activation, these studies reveal a drug delivery strategy with potential to augment therapies against multiple cancer types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · cited 1×
“Indeed, in some tumors, stroma can comprise up to 90% of the total tumor mass (6, 7).”
BackgroundThe biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Carcinoma-associated fibroblasts stimulate tumor progression of initiated human epithelium
Olumi, A., Grossfeld, G., Hayward, S., Carroll, P., Cunha, G., Hein, P., & Tlsty, T. (2000) · Breast Cancer Research · doi:10.1186/bcr138 · Cited by 1,463
Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T. (2010) · Science · doi:10.1126/science.1195300 · Cited by 1,134
Tanaka, H., Matsushima, H., Nishibu, A., Clausen, B. E., & Takashima, A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1106 · Cited by 134
Cited by
Tumor angiogenesis: causes, consequences, challenges and opportunities
Lugano, R., Ramachandran, M., & Dimberg, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03351-7 · Cited by 1,986
Turning cold tumors into hot tumors by improving T-cell infiltration
Liu, Y.-T., & Sun, Z.-J. (2021) · Theranostics · doi:10.7150/thno.58390 · Cited by 827
Antibody–drug conjugates for cancer
Chau, C. H., Steeg, P. S., & Figg, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31774-x · Cited by 816
Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
Subhan, M. A., Yalamarty, S. S. K., Filipczak, N., Parveen, F., & Torchilin, V. P. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060571 · Cited by 623
“ADC might overcome heterogeneity of tumors by utilizing TME to facilitate cleavage of linkers and payload release [16].”
MethodAntibody-Drug Conjugate-Based Therapeutics: State of the Science
Birrer, M. J., Moore, K. N., Betella, I., & Bates, R. C. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz035 · Cited by 439
Metadata
- Authors
- Szot, C., Saha, S., Zhang, X. M., Zhu, Z., Hilton, M. B., Morris, K., Seaman, S., Dunleavey, J. M., Hsu, K.-S., Yu, G.-J., Morris, H., Swing, D. A., Haines, D. C., Wang, Y., Hwang, J., Feng, Y., Welsch, D., DeCrescenzo, G., Chaudhary, A., Zudaire, E., Dimitrov, D. S., & St. Croix, B.
- Venue
- Journal of Clinical Investigation
- Published
- 2018-06-04
- Volume
- 128
- Issue
- 7
- Pages
- 2927-2943
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2806009225
- Cited by
- 127
- References
- 8
- FWCI
- 7.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor stroma–targeted antibody-drug conjugate triggers localized anticancer drug release. https://app.cochat.ai/papers/10.1172/jci120481
- The paper
- Szot, C., Saha, S., Zhang, X. M., Zhu, Z., Hilton, M. B., Morris, K., Seaman, S., Dunleavey, J. M., Hsu, K.-S., Yu, G.-J., Morris, H., Swing, D. A., Haines, D. C., Wang, Y., Hwang, J., Feng, Y., Welsch, D., DeCrescenzo, G., Chaudhary, A., . . . St. Croix, B. (2018). Tumor stroma–targeted antibody-drug conjugate triggers localized anticancer drug release. Journal of Clinical Investigation. https://doi.org/10.1172/jci120481
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.